Om

Metis TechBio Co., Ltd. is a biotechnology company specializing in AI-driven drug formulation and nanomaterial-based delivery technologies. Headquartered in China and founded in 2020, the company operates at the intersection of artificial intelligence, molecular simulation, quantum chemistry, and advanced drug delivery. Metis TechBio focuses on optimizing how active pharmaceutical ingredients are formulated and delivered, aiming to improve therapeutic performance, stability, and patient convenience.

Its core technology platforms include NanoForge for nano-delivery design, AiTEM for small-molecule formulation, AiLNP for nucleic acid delivery systems, and AiRNA for mRNA sequence optimization. These platforms support applications in human therapeutics, longevity-related products, and animal health. Metis TechBio develops proprietary drug candidates leveraging these systems, particularly in areas such as neurological disorders and other conditions where targeted or enhanced delivery can provide clinical benefits. The company primarily serves pharmaceutical and biotech partners seeking advanced formulation solutions and differentiated delivery technologies, positioning itself as a specialized enabler within the broader life sciences and healthcare ecosystem.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I METIS TECHBIO CO MED ENDAVU: Køb Metis TechBio Co ($7666) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Metis TechBio Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.